Continuous disclosure is a key challenge for boards of ASX-Listed companies. The obligation of “immediate” disclosure of market-sensitive information leads to Boards needing to make quick decisions, sometimes based on incomplete information.
For life sciences companies, there are added complexities:
- providing balanced and clear explanations of highly technical information such as clinical trial results; and
- keeping a reasonable flow of announcements over the long development timeline.
We invite you to join our roundtable event, where corporate partners of Piper Alderman will share insights on navigating this challenging aspect of life as a listed company.
There will be plenty of time for Q & A, along with your peers in the sector, under Chatham House Rule.
|Wednesday, 14 September|
|Level 23, 459 Collins Street|
|Duration:||Up to 90 minutes|
|Limited seating at each breakfast|
The workshops are open to all organisations, excluding other legal service providers.